Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026)
Cardiol Therapeutics (CRDL) reported Income from Continuing Operations of 6931880.35 for Q1 2026, down 21.58% on a YoY basis from 8839830.89 in Q1 2025, and up 6.29% quarter-over-quarter from 7397216.99 in Q3 2025.
Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cardiol Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 6931880.35 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 21.58% year-over-year to 6931880.35; the trailing twelve-month figure through Mar 2026 stood at 25570406.65 (up 8.56% YoY), and the FY2025 full-year result was 24086852.95, up 13.91% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6931880.35, up from 7397216.99 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4700956.01 in Q2 2023, with the low at 10365668.44 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 6843628.97 across 5 years, with a median of 6469070.64 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 43.66% — and 2024, when it tumbled 81.51%.
- Cardiol Therapeutics' Income from Continuing Operations stood at 6700322.82 in 2022, then increased by 14.77% to 5710762.37 in 2023, then plunged by 81.51% to 10365668.44 in 2024, then increased by 28.64% to 7397216.99 in 2025, then climbed by 6.29% to 6931880.35 in 2026.
- The last three Income from Continuing Operations figures came in at 6931880.35 (Q1 2026), 7397216.99 (Q3 2025), and 5539979.18 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Cardiol Therapeutics | 168.37 Mn | 148.19 Mn | - | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Sep 30, 2025 | -7.40 Mn |
| Jun 30, 2025 | -5.54 Mn |
| Mar 31, 2025 | -5.70 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -4.70 Mn |
| Mar 31, 2023 | -5.76 Mn |
| Dec 31, 2022 | -6.70 Mn |
| Sep 30, 2022 | -10.14 Mn |
| Jun 30, 2022 | -7.24 Mn |
| Mar 31, 2022 | -7.73 Mn |
| Dec 31, 2021 | -10.39 Mn |
| Sep 30, 2021 | -8.01 Mn |
| Jun 30, 2021 | -5.19 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -7.38 Mn |
| Sep 30, 2020 | -3.27 Mn |